Francesca Del Monte

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore et al. · The Lancet Oncology · 2010 · 240 citations

Medicine, Oncology, Pharmacology +10

Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study

Stuart H. Ralston, André G. Uitterlinden, Maria Luisa Brandi et al. · PLoS Medicine · 2006 · 183 citations · Full text

Medicine, Genetics, Molecular Genetics +17

A Polymorphic CYP19 TTTA Repeat Influences Aromatase Activity and Estrogen Levels in Elderly Men: Effects on Bone Metabolism

Luigi Gennari, Laura Masi, Daniela Merlotti et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 158 citations · Full text

Medicine, Endocrinology, Genetics +17

Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer

Veronica Ghini, Letizia Laera, Beatrice Fantechi et al. · Cancers · 2020 · 139 citations · Full text

Life Sciences, Immunology, Oncology +17

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo et al. · Annals of Oncology · 2014 · 90 citations · Full text

Medicine, Oncology, Chemotherapy +10